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Antiepiligrin cicatricial pemphigoid (AECP) is a chronic autoimmune subepidermal blistering disease
characterized by clinical features of cicatricial pemphigoid and circulating IgG antibasement membrane
autoantibodies directed against laminin 332. There is growing evidence of an increased relative risk for
solid cancers and lymphomas in AECP patients, especially in the 1st year after the onset of blisters.
However, it is difﬁcult to distinguish patients with initially skin-predominant AECP from similar ﬁndings
of epidermolysis bullosa acquisita merely based on clinical, histopathologic, and immuno-pathologic
examinations. This is a report on a case of AECP conﬁrmed by indirect immunoﬂuorescence of type
VII collagen- and laminin 332-deﬁcient skin as substrates to differentiate it from epidermolysis bullosa
acquisita.
Copyright  2011, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Antiepiligrin cicatricial pemphigoid (AECP) is a mucosa-
predominant autoimmune subepidermal blistering disease that is
clinically indistinguishable from other forms of cicatricial pem-
phigoid1 (CP). The importance of deﬁning AECP within the spec-
trum of mucosa-predominant blistering diseases by immunoblot,
immunoprecipitation, or indirect immunoﬂuorescence (IF) using
antigen-deﬁcient skin substrates2,3 is emphasized by its association
with cancer and increased cancer-related morbidity and mortal-
ity.4e6 This report is of a case of initially skin-predominant AECP,
which is distinguished from epidermolysis bullosa acquisita (EBA)
using indirect IF of Type VII collagen- and laminin 332-deﬁcient
skin as substrates. The clinical course and histo- and immuno-
pathologic ﬁndings are presented.
Case report
A 33-year-old male patient presented with a 1-month history of
multiple pruritic tense blisters overlying the erythematous basesgy, Buddhist Tzu-Chi General
n 970, Taiwan.
g).
iwanese Dermatological Associatioinitially on the dorsum of both hands and feet, then centripetally
spreading to both arms, thighs, and trunk without mucosal lesions.
His past history was unremarkable except for gout under treatment
with colchicine and benzbromazone for several years. Laboratory
ﬁndings showed negative antinuclear antibody (<1:40), rheuma-
toid factor, and other autoimmune proﬁles. The patient also did not
fulﬁll the American Rheumatism Association criteria for systemic
lupus erythematosus (LE).
Histological examination of the cutaneous biopsy specimens
revealed subepidermal blister with predominant neutrophilic
inﬁltration mixed with some eosinophils (Figure 1). Direct IF
showed linear C3 and IgG deposition along the basement
membrane zone (BMZ), whereas indirect IF revealed circulating
IgG antibasement membrane autoantibodies binding to dermal
ﬂoor of the 1M NaCl split skin7 (Figure 2). With a tentative
diagnosis of EBA, prednisolone 0.7 mg/kg/d was started. However,
progressive blisters on the trunk and four extremities with
concurrent oral and genital mucosal erosions developed after 2
weeks, and some blisters ruptured with scarring and milia
formation (Figures 3A and 3B). Indirect IF on antigen-deﬁcient
skin substrates showed positive reactions with the BMZ on Type
VII collagen-deﬁcient skin and negative ﬁndings on laminin
332-deﬁcient skin2,3 (Figures 4A and 4B), leading to a diagnosis
of AECP.n. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 A subepidermal blister with predominant neutrophilic inﬁltration mixed
with some eosinophils on the right forearm (hematoxylin-eosin stain, 200).
C.-P. Chen et al. / Dermatologica Sinica 29 (2011) 55e5856The patient was then shifted to azathioprine 150 mg/d and
prednisone 1 mg/kg/d, with good control. Further work-up for
malignancy, including serologic tumor markers, chest X-rays,
abdominal ultrasound, panendoscopy, and colon ﬁberscopy, were
negative. The patient was in his stable condition during treatment
for about half a year, but he was loss to follow-up thereafter.
Discussion
CP, also known as mucous membrane pemphigoid, is an autoim-
mune subepidermal blistering disease predominantly involving the
mucous membrane and occasionally involving the skin in up to 30%
of patients.1 Patients with CP exhibit IgG and/or IgA autoantibodies
directed against heterogeneous components of the BMZ, including
BPAG1, BPAG2, laminin 332, Type VII collagen, a6-integrin subunit,Figure 2 Indirect immunoﬂuorescence revealed circulating IgG antibasement
membrane autoantibodies binding to the dermal ﬂoor of 1M NaCl split skin (160).
Figure 3 (A) Multiple oral mucosal erosions and hemorrhagic vesicle over palate and
buccal mucosa. (B) Multiple tense blisters overlying the erythematous base over the
dorsum of the right hand and some vesicles ruptured with scarring and milia
formation.or b4-integrin subunit.1,5 Indirect IF studies of 1M NaCl split skin
show that IgG autoantibodies from CP patients can bind to the
epidermal side, dermal side, and even both sides of test substrates,
depending on which autoantigens are the targets.1
AECP, ﬁrst described by Domloge-Hultsch et al in 1992, is
characterized by clinical features of CP and circulating IgG anti-
basement membrane autoantibodies directed against laminin 332.1
It is estimated to comprise 5e20% of CP cases.5 It typically affects
the elderly, with the median age of onset at 65 years and occurs
with equal frequency in men and women.4,5 The clinical features of
AECP are characterized by erosive and/or vesiculobullous lesions
that usually heal with scarring and tissue destruction. Mucosal
sites most commonly involved are the mouth and eyes.5 Other
mucosal sites, including the nose, pharynx, larynx, esophagus, and
anogenital region, are less commonly involved. However, skin
involvement is not a dominant feature.5 Direct IF studies of per-
ilesional mucous membrane or skin biopsy specimen show linear
deposits composed mainly of IgG, and sometimes C3, in the
epidermal BMZ.5 Indirect IF studies reveal binding of IgG anti-
basement membrane autoantibodies exclusively to the dermal side
of 1M NaCl split skin.1,5
Figure 4 Indirect immunoﬂuorescence revealed (A) positive reaction on Type VII collagen-deﬁcient skin and (B) negative reaction on laminin 332-deﬁcient skin (160).
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the diagnosis of AECP.5 We reviewed the literatures about anti-
laminin 332 autoantibodies in patients with immunobullous
diseases, including bullous pemphigoid (BP), EBA, AECP, and other
CPs except AECP,8e13 the results are summarized in Table 1. Most of
these studies used enzyme-linked immunosorbent assay (ELISA) to
detect antilaminin 332 autoantibodies or immunoblotting or
immunoprecipitation to detect laminin 332 in human keratino-
cytes (HKs) extracts. Lazarova et al8 found that 3 of 34 (8.8%) and 13
of 100 (13%) BP patients’ sera were detected with antilaminin 332
IgG4 by ELISA, but none of these patients’ sera could immunoblot or
immunoprecipitate laminin 332 from HKs extracts. Bekou et al9
found that 29 of 72 (40.3%) BP patients’ sera were detected with
antilaminin 332 IgG by ELISA, but the disease severities did not
correlate with the levels of antilaminin 332 IgG. Lazarova et al8
explained that this elevated frequency of false-positive ELISA
results among BP patients may be because of elevated serum level
of other IgG4 and the use of a conjugated antihuman IgG as
a second step antibodyda polyclonal reagent that yielded high
background reactivity against laminin 332. None of the patients’
sera from EBA or other CPs except AECP could either immunoblot or
immunoprecipitate laminin 332 in HKs extracts.10e13 Although
patients with other undeﬁned immunobullous diseases had beenTable 1 Detection of antilaminin 332 autoantibodies in patients with immunobullous d
Method AECP
Anti-laminin 332 autoantibodies ELISA 29/32 (
Immunoblotting 30/32 (
8/9 (88
Immunoprecipitation 32/32 (
9/9 (10
Data are presented as n (%).
AECP¼ antiepiligrin cicatricial pemphigoid; BP¼ bullous pemphigoid; CP¼ cicatricial p
nosorbent assay.reported to have antilaminin 332 autoantibodies by ELISA, immu-
noblotting, or immunoprecipitation, these were relatively rare
cases reported.14,15 And most of these case reports showed circu-
lating IgG and/or C3 binding to epidermal side or both epidermal
and dermal side of 1M NaCl split skin by indirect IF.14,15 In
conclusion, the presence of antilaminin 332 autoantibodies is
essential for the diagnosis of AECP and has pathogenic activities
in vivo by passive transfer animal models.16e18
It is difﬁcult to distinguish patients with initially skin-
predominant AECP from similar ﬁndings of EBA based only on
clinical and histo- and immunopathologic examinations. Indirect
IF with 1M NaCl split skin7 can differentiate BP from AECP, EBA,
and bullous LE because IgG binds to the epidermal roof of 1M NaCl
split skin in BP, in contrast to the dermal ﬂoor in the other
three immunobullous diseases. Clinical information, including the
American Rheumatism Association criteria for systemic LE and
positive lupus serology, can help differentiate bullous LE from
AECP and EBA. The more sensitive techniques, such as ELISA,
western immunoblotting, immunoprecipitation, and immunoe-
lectron microscopy, can conﬁrm the ﬁnal diagnosis of different
subepidermal immunobullous diseases. However, these are often
time consuming and expensive. Diagnostic indirect IF on antigen-
deﬁcient substrates2,3 of Type VII collagen-deﬁcient or lamininiseases by ELISA, immunoblotting, or immunoprecipitation.
EBA CP
(except AECP)
BP
90.6)8 3/34 (8.8)8
13/100 (13)8
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emphigoid; EBA¼ epidermolysis bullosa acquisita; ELISA¼ enzyme-linked immu-
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junctional epidermolysis bullosa, respectively, can provide a rapid
and simple test to help clinicians differentiate between AECP and
EBA. If indirect IF on antigen-deﬁcient skin substrates showpositive
reaction on Type VII collagen-deﬁcient skin and negative ﬁnding on
laminin 332-deﬁcient skin, this demonstrates that the patient’s
serum contains antilaminin 332 autoantibodies instead of anti-
Type VII collagen autoantibodies. Hence, AECP is diagnosed and
vice versa. Two added indirect IF tests can provide a double check
and improve the speciﬁcity and sensitivity of diagnosis.
It is of signiﬁcant importance to distinguish AECP from other
immunobullous diseases because of increased relative risk (RR) of
developing solid cancers or lymphomas, especially in the 1st year
after the onset of blisters.4e6 A cohort study of 35 patients with
AECP in a 12-year follow-up period showed a RR of 6.8, with 10
patients having a solid cancer. The RR increased up to 15.4 in the
1st year after the blister onset.4,5 All the solid cancers reported
in this cohort study were adenocarcinoma of visceral origin,
including the lungs, stomach, colon, and uterus.4,5 The 10 AECP
patients who developed cancers died during follow-up and all
deaths were cancer related, occurring within 21 months of cancer
diagnosis.4,5 Another review study revealed two patients with
AECP having diffuse large B-cell lymphoma and cutaneous T-cell
lymphoma, respectively.6 Thus, patients with AECP have a higher
morbidity and mortality rate than other immunobullous diseases
because of their association with cancers. Age-appropriate cancer
screening is therefore recommended in patients diagnosed with
AECP.4e6
The mechanism of association of AECP with cancer is still
unknown, but laminin 332 seems to play a central role.5 Laminin
332, a heterotrimeric adhesion protein consisting of a3b3g2
subunits, is expressed in the basement membrane of normal
epithelia and in the extracellular matrix of various malignancies.5
AECP is considered a paraneoplastic syndrome, a condition char-
acterized by an autoimmune response to laminin 332 present in
both normal skin and the underlying malignancy.5 This is sup-
ported by observations that clinical disease activity of AECP
correlates with total tumor mass.1,5 That is, the clinical disease
activity of AECP is markedly reduced when the primary tumor is
partially or completely removed, and metastasis or cancer recur-
rence is associated with recurrent or high disease activity.1,5
Treatment of all subsets of CP, including AECP, is similar. It
depends on disease location, extent, and severity.19 In limited
mucosal or cutaneous lesions, topical or intralesional glucocorti-
coids with topical anesthetic agents and oral hygiene may sufﬁce.19
While in extensive or progressive disease, systemic agents are
warranted as following. Dapsone and tetracycline have been
reported to be effective in some patients.19 If there is poor response
to both agents, systemic glucocorticoid in combination with
immunosuppressive agents, such as cyclophosphamide, azathio-
prine, or mycophenolate mofetil, are indicated.19 High dose intra-
venous immunoglobulin is reserved for patients who are refractory
to the above-mentioned therapies.19 During treatment of AECP,
early detection of solid cancer or lymphoma is important to
decrease the cancer-related morbidity and mortality.In conclusion, this is a report of a middle-aged male patient
with an initial skin-predominant AECP, which was distinguished
from EBA using indirect IF of Type VII collagen- and laminin
332-deﬁcient skin. The patient had good response to systemic
treatment with azathioprine and prednisolone. The relationship of
AECP with cancers and the effect on prognosis warrant long-term
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